-
公开(公告)号：JP2013253089A
公开(公告)日：2013-12-19
申请号：JP2013160858
申请日：2013-08-01
Applicant: PHARMACYCLICS INC
Inventor： HONIGBERG LEE , VERNER ERIK , BUGGY JOSEPH J , LOURY DAVID , CHEN WEI
IPC: C07D487/04 , A61K31/437 , A61K31/4985 , A61K31/519 , A61K31/5377 , A61P29/00 , A61P35/00 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04
Abstract: PROBLEM TO BE SOLVED: To provide an irreversible Bruton's kinase inhibitor compound to be used in treatment of diseases.SOLUTION: There is provided a compound illustrated in formulae.
-
公开(公告)号：JP2012105681A
公开(公告)日：2012-06-07
申请号：JP2012049524
申请日：2012-03-06
Applicant: Pharmacyclics Inc , ファーマサイクリクス,インコーポレイテッド
Inventor： HONIGBERG LEE , VERNER ERIK , PAN ZHENGYING
IPC: C12N9/12 , A61K31/519 , A61P1/04 , A61P1/16 , A61P3/02 , A61P3/10 , A61P5/00 , A61P7/06 , A61P9/00 , A61P13/10 , A61P15/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P21/04 , A61P25/00 , A61P29/00 , A61P37/06 , A61P43/00 , C07D487/04
CPC classification number: A61K31/52 , A61K9/4825 , A61K31/00 , A61K31/519 , A61K39/3955 , A61K45/06 , C07D487/04 , C07K16/2887 , C07K2317/24 , A61K2300/00
Abstract: PROBLEM TO BE SOLVED: To bring advantages on the therapy of patients having related diseases by inhibiting the activity of tyrosine kinase.SOLUTION: There are provided: compounds that form covalent bonds with Bruton's tyrosine kinase (Btk); irreversible inhibitors of Btk; methods for the preparation of the compounds; pharmaceutical compositions that include the compounds; and also methods of using the Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Abstract translation: 要解决的问题：通过抑制酪氨酸激酶的活性，为治疗患有相关疾病的患者带来优势。 提供：与Bruton酪氨酸激酶（Btk）形成共价键的化合物; Btk不可逆抑制剂; 化合物的制备方法; 包括化合物的药物组合物; 以及使用Btk抑制剂单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症的方法。 版权所有（C）2012，JPO＆INPIT
-
公开(公告)号：JP2010235628A
公开(公告)日：2010-10-21
申请号：JP2010155965
申请日：2010-07-08
Applicant: Pharmacyclics Inc , ファーマサイクリクス,インコーポレイテッド
Inventor： HONIGBERG LEE , VERNER ERIK , PAN ZHENGYING
IPC: C07D487/04 , A61K31/519 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/06 , A61P9/00 , A61P11/06 , A61P13/02 , A61P15/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P21/04 , A61P35/00 , A61P35/02 , A61P37/06 , A61P37/08 , A61P43/00
CPC classification number: A61K31/52 , A61K9/4825 , A61K31/00 , A61K31/519 , A61K39/3955 , A61K45/06 , C07D487/04 , C07K16/2887 , C07K2317/24 , A61K2300/00
Abstract: PROBLEM TO BE SOLVED: To inhibit the activity of tyrosine kinase and to bring advantages on the therapy of patients of related diseases. SOLUTION: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk), also described are irreversible inhibitors of the Btk, methods for the preparation of the compounds, also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancers including lymphoma, and inflammatory diseases or conditions. COPYRIGHT: (C)2011,JPO&INPIT
Abstract translation: 要解决的问题：抑制酪氨酸激酶的活性，为相关疾病患者的治疗带来好处。 本文公开了与Bruton酪氨酸激酶（Btk）形成共价键的化合物，也描述了Btk的不可逆抑制剂，制备化合物的方法，还公开了包含该化合物的药物组合物。 公开了使用Btk抑制剂的方法，单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫疾病或病症，包括淋巴瘤和炎性疾病或病症的癌症。 版权所有（C）2011，JPO＆INPIT
-
公开(公告)号：JP2013060466A
公开(公告)日：2013-04-04
申请号：JP2012286719
申请日：2012-12-28
Applicant: Pharmacyclics Inc , ファーマサイクリクス,インコーポレイテッド
Inventor： HONIGBERG LEE , VERNER ERIK , PAN ZHENGYING
IPC: C07D487/04 , A61K31/519 , A61P35/00
CPC classification number: A61K31/52 , A61K9/4825 , A61K31/00 , A61K31/519 , A61K39/3955 , A61K45/06 , C07D487/04 , C07K16/2887 , C07K2317/24 , A61K2300/00
Abstract: PROBLEM TO BE SOLVED: To provide therapeutic benefit to a patient having relevant diseases by inhibiting tyrosine kinase activity.SOLUTION: There are provided: compounds that form covalent bonds with Bruton's tyrosine kinase (Btk); irreversible inhibitors of Btk; methods for the preparation of the compounds; pharmaceutical compositions that include the compounds; and methods of using the Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Abstract translation: 待解决的问题：通过抑制酪氨酸激酶活性为具有相关疾病的患者提供治疗益处。 提供：与Bruton酪氨酸激酶（Btk）形成共价键的化合物; Btk不可逆抑制剂; 化合物的制备方法; 包括化合物的药物组合物; 以及使用Btk抑制剂单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症的方法。 版权所有（C）2013，JPO＆INPIT
-
5.发明申请INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS 审中-公开用于治疗固体肿瘤的BRUTON的酪氨酸激酶的抑制剂
公开(公告)号：WO2010009342A3
公开(公告)日：2010-05-14
申请号：PCT/US2009050897
申请日：2009-07-16
Applicant: PHARMACYCLICS INC , HONIGBERG LEE , VERNER ERIK , BUGGY JOSEPH , LOURY DAVID , CHEN WEI
Inventor： HONIGBERG LEE , VERNER ERIK , BUGGY JOSEPH , LOURY DAVID , CHEN WEI
CPC classification number: A61K31/519 , A61K31/00 , A61K31/337 , A61K31/52 , A61K31/675 , A61K31/704 , A61K33/24 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2300/00 , A61K31/19
Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
Abstract translation: 本文描述的是不可逆的Btk抑制剂化合物，以及使用这种不可逆抑制剂治疗以固体肿瘤的存在或发展为特征的疾病和病症的方法。
-
Patent Agency Ranking
公开(公告)号：WO2008039218A3
公开(公告)日：2008-05-29
申请号：PCT/US2006049626
申请日：2006-12-28
Applicant: PHARMACYCLICS INC , HONIGBERG LEE , VERNER ERIK , PAN ZHENGYING
Inventor： HONIGBERG LEE , VERNER ERIK , PAN ZHENGYING
IPC: A01N43/90 , A61K31/519
CPC classification number: A61K31/52 , A61K9/4825 , A61K31/00 , A61K31/519 , A61K39/3955 , A61K45/06 , C07D487/04 , C07K16/2887 , C07K2317/24 , A61K2300/00
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Abstract translation: 本文公开了与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。 还描述了Btk的不可逆抑制剂。 公开了制备这些化合物的方法。 还公开了包含该化合物的药物组合物。 单独或与其他治疗剂组合使用Btk抑制剂的方法用于治疗自身免疫疾病或病症，异质性免疫疾病或病症，癌症（包括淋巴瘤）和炎性疾病或病症。
-
公开(公告)号：WO2008054827A2
公开(公告)日：2008-05-08
申请号：PCT/US2007023306
申请日：2007-11-05
Applicant: PHARMACYCLICS INC , PAN ZHENGYING , LI SHYR JIANN , SCHEREENS HELEEN , HONIGBERG LEE , VERNER ERIK
Inventor： PAN ZHENGYING , LI SHYR JIANN , SCHEREENS HELEEN , HONIGBERG LEE , VERNER ERIK
IPC: G01N33/574
CPC classification number: C07D487/04 , G01N33/573 , G01N2333/9121 , G01N2500/00
Abstract: Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.
Abstract translation: 本文描述了布鲁顿酪氨酸激酶（Btk）的探针。 这些探针用于表征和开发预期用于治疗用途的Btk选择性抑制剂。
-
公开(公告)号：WO2008121742A3
公开(公告)日：2008-11-27
申请号：PCT/US2008058528
申请日：2008-03-27
Applicant: PHARMACYCLICS INC , HONIGBERG LEE , VERNER ERIK , BUGGY JOSEPH J , LOURY DAVID , CHEN WEI
Inventor： HONIGBERG LEE , VERNER ERIK , BUGGY JOSEPH J , LOURY DAVID , CHEN WEI
IPC: A61K31/52 , A61K31/519 , A61P29/00 , A61P35/00 , C07D253/06 , C07D473/34 , C07D487/04
CPC classification number: C07D487/04 , A61K31/52 , C07D471/04 , C12Q1/485 , G01N33/57426 , G01N2440/14 , G01N2500/00
Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
Abstract translation: 本文描述的是不可逆激酶抑制剂化合物，用于合成这种不可逆抑制剂的方法，以及使用这种不可逆抑制剂治疗疾病的方法。 本文进一步描述了用于确定包括激酶在内的蛋白质的合适的不可逆抑制剂的方法，测定和系统。
-
公开(公告)号：WO2007087068A3
公开(公告)日：2008-02-21
申请号：PCT/US2006049489
申请日：2006-12-28
Applicant: PHARMACYCLICS INC , JANKOWSKI ORION D , PALMER JAMES T , HONIGBERG LEE
Inventor： JANKOWSKI ORION D , PALMER JAMES T , HONIGBERG LEE
IPC: C07D471/06 , A61K31/416 , A61K31/4375 , A61K31/675
CPC classification number: C07D471/04 , C07F9/65685 , C07F9/65846
Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-rnediated diseases or conditions or tyrosine, kinase-dependent diseases or conditions are provided.
Abstract translation: 本文公开了抑制特定酪氨酸激酶活性的化合物。 公开了制备这些化合物的方法。 还公开了包含化合物的药物组合物。 提供了将单独或与其它治疗剂组合公开的化合物用于治疗酪氨酸激酶受体疾病或病症或酪氨酸，激酶依赖性疾病或病症的方法。
-
公开(公告)号：EP2089391A4
公开(公告)日：2010-03-17
申请号：EP07867362
申请日：2007-11-05
Applicant: PHARMACYCLICS INC
Inventor： PAN ZHENGYING , LI SHYR JIANN , SCHEREENS HELEEN , HONIGBERG LEE , VERNER ERIK
IPC: C07D487/00 , C07D487/04 , G01N33/573
CPC classification number: C07D487/04 , G01N33/573 , G01N2333/9121 , G01N2500/00
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.029 seconds)
